S2104 Study
1-800-641-2422
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
- Sex: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase I
- Conditions Being Studied: Cancer - Neuroendocrine, Cancer - Pancreas
Study Purpose
The purpose of this study is to evaluate recurrence-free survival in participants with resected pancreatic neuroendocrine tumors (pNETs) randomized to treatment with capecitabine + temozolomide (CAPTEM) compared to observation only.
Who Can Participate
Participants 18 years old and older may be eligibile if the patient has high-risk pancreatic neuroendocrine tumors. Patient may have received resection/ablation of liver oligo-metastatic disease (up to 5 liver metastases) at the time of the pNET resection. Eligible patients cannot currently have liver metastasis.
Locations
UH Seidman Cancer Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: CIRB
- StudyID: S2104
- ClinicalTrials.gov: NCT05040360
1-800-641-2422
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422